Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AX Other immunosuppressants
L04AX06 Pomalidomide
D08976 Pomalidomide (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Immunomodulatory Agents
Imides
Pomalidomide
D08976 Pomalidomide (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D08976 Pomalidomide (JAN/USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
D08976 Pomalidomide
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D08976 Pomalidomide
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Interleukins
IL6
D08976 Pomalidomide (JAN/USAN/INN) <JP/US>
Tumor necrosis factors
TNF (TNFA, TNFSF2)
D08976 Pomalidomide (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D08976
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08976
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D08976
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D08976
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D08976